查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1507901

ePRO、电子病患日记和 eCOA 的全球市场

ePRO, E-Patient Diaries and eCOA
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 411 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球 ePRO、电子病患日记和 eCOA 市场规模将达到 47 亿美元

全球ePRO、电子病患日记和eCOA市场规模预计在2023年达到18亿美元，并在2023-2030年分析期间以15.0%的复合年增长率增长，到2030年将达到47亿美元。在分析期间，ePRO 产业的复合年增长率预计为 16.7%。

美国市场预计将达6.298亿美元，中国预计复合年增长率为17.9%

美国ePRO、电子病人日记和eCOA市场规模预计到2023年将达到6.298亿美元，而中国作为全球第二大经济体，预计到2030年将达到6.046亿美元。年分析期间为17.9%。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 12.4% 和 14.3%。在欧洲，德国的复合年增长率预计约为 13.6%。

全球 ePRO、电子病患日记和 eCOA 市场 – 主要趋势和驱动因素总结

ePRO（电子病患日记或 eCOA）是一个数位平台，用于直接从临床试验和临床环境中的病患收集资料。 ePRO 系统通常透过行动装置或其他基于网路的应用程式以电子方式收集有关健康状况、治疗依从性和症状的患者资料。电子病患日记为病患提供了记录日常健康观察的数位方式，对于慢性病的管理特别有用。 eCOA 包含这些工具，包括透过数位介面收集的临床医生报告的结果 (ClinROs)、观察者报告的结果 (ObsROs) 和绩效结果 (PerfOs)。这些工具旨在取代纸本方法，目的是提高资料收集准确性、增强患者参与度并简化即时收集复杂健康资料的过程。

ePRO、电子病患日记和 eCOA 系统的实施是由医疗保健的数位转型和製药业对以病患为中心的研究的重视所推动的。透过利用这些数位工具，临床研究人员可以获得更可靠、更及时的资料，以提高临床试验的品质和效率。这些技术还透过确保协议合规性并促进即时监控和审核功能来支援监管合规性。对于患者来说，数位工具提供了在家参加试验的便利，并透过及时提醒和与医疗保健提供者的便利沟通管道来提高对试验通讯协定的遵守情况。此外，这些技术对于长期试验至关重要，在长期试验中，持续的患者参与和准确的资料收集至关重要。

ePRO、电子病患日记和 eCOA 市场的成长受到多种因素的推动，包括行动医疗应用的技术进步以及对远端医疗实践的日益接受。随着智慧型手机和平板电脑变得越来越普遍，更多的患者和临床医生可以轻鬆使用复杂的健康监测工具。监管机构和卫生当局越来越认识到即时患者资料在改善临床结果方面的价值，这推动了这些系统在全球医疗保健和研究环境中的采用。此外，以患者为中心的治疗方法不断增长的需求以及临床试验中高效资料管理的需求是该市场的主要驱动力。消费者对医疗技术的行为发生了巨大变化，患者现在期望在管理自己的健康方面发挥更积极的作用，这与 ePRO、电子病患日记和 eCOA I am 的功能非常吻合。这些趋势，加上疫情后对数位健康解决方案的持续推动，支撑了市场的动态扩张和演变。

受访企业范例（共85家）

  • Anju Software, Inc.
  • ArisGlobal LLC
  • Castor EDC
  • Clario
  • Climedo Health GmbH
  • ClinCapture
  • Dassault Systemes SE
  • eClinical Solutions LLC
  • ICON plc
  • IQVIA Holdings, Inc.
  • Kayentis, SAS
  • MedNet Solutions, Inc.
  • Signant Health
  • TransPerfect

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 欧洲其他地区
  • 亚太地区
  • 其他地区

第四章 比赛

简介目录
Product Code: MCP11846

Global ePRO, E-Patient Diaries and eCOA Market to Reach US$4.7 Billion by 2030

The global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.8 Billion in the year 2023, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2023-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the ePatient Reported Outcomes (ePROs) segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$629.8 Million While China is Forecast to Grow at 17.9% CAGR

The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$629.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$604.6 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.4% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global ePRO, E-Patient Diaries and Ecoa Market- Key Trends and Drivers Summarized

Electronic Patient-Reported Outcomes (ePROs), e-Patient Diaries, and electronic Clinical Outcome Assessments (eCOAs) are digital platforms used in clinical trials and healthcare settings to collect data directly from patients. ePRO systems are used to electronically capture patient data on health status, treatment adherence, and symptoms, usually via mobile devices or other web-based applications. E-Patient Diaries provide patients with a digital means to record daily observations about their health condition, which can be particularly valuable for chronic diseases management. eCOAs encompass these tools and extend to include clinician-reported outcomes (ClinROs), observer-reported outcomes (ObsROs), and performance outcomes (PerfOs) gathered through digital interfaces. These tools are designed to replace paper-based methods, aiming to improve the accuracy of data collection, enhance patient engagement, and streamline the process of capturing complex health data in real time.

The adoption of ePRO, e-Patient Diaries, and eCOA systems is being propelled by the digital transformation in healthcare and the pharmaceutical industry’s focus on patient-centered research. By utilizing these digital tools, clinical researchers can obtain more reliable and timely data, enhancing the quality and efficiency of clinical trials. These technologies also support regulatory compliance by ensuring adherence to protocols and facilitating real-time monitoring and auditing capabilities. For patients, digital tools offer the convenience of participating in studies from home and improve compliance with study protocols through timely reminders and easier communication channels with healthcare providers. Moreover, these technologies are integral in long-term studies where consistent patient engagement and accurate data collection over extended periods are crucial.

The growth in the ePRO, e-Patient Diaries, and eCOA market is driven by several factors, including technological advancements in mobile health applications and increased acceptance of telehealth practices. As smartphones and tablets become more prevalent, more patients and clinicians are able to access sophisticated health monitoring tools with ease. Regulatory bodies and health authorities are increasingly recognizing the value of real-time patient data in improving clinical outcomes, which is encouraging the adoption of these systems across global healthcare and research settings. Additionally, the growing demand for patient-centric treatment approaches and the need for efficient data management in clinical trials are key drivers of this market. Consumer behavior towards health technology has shifted dramatically, with patients now expecting more active roles in managing their health, which aligns well with the capabilities of ePROs, e-Patient Diaries, and eCOAs. These trends, combined with the ongoing push for digital health solutions post-pandemic, underscore a dynamic expansion and evolution in the market.

Select Competitors (Total 85 Featured) -

  • Anju Software, Inc.
  • ArisGlobal LLC
  • Castor EDC
  • Clario
  • Climedo Health GmbH
  • ClinCapture
  • Dassault Systemes SE
  • eClinical Solutions LLC
  • ICON plc
  • IQVIA Holdings, Inc.
  • Kayentis, SAS
  • MedNet Solutions, Inc.
  • Signant Health
  • TransPerfect

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Pivotal Role of eCOA, ePRO and Patient Engagement in Transforming Patient Centricity
    • An Introduction to ePRO, E-Patient Diaries and eCOA
    • Influencer Market Insights
    • Global Economic Update
    • Global Market Outlook
    • eCOA: The Largest Category
    • ePRO Offers Tremendous Opportunities in Improving Healthcare System
    • Competition
    • ePRO, E-Patient Diaries and eCOA - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth
    • Global Digital Health Market: Annual Revenues in US$ Million by Region/Country for 2020 and 2027
    • Patient Engagement Practices of the Future to be Shaped by Trends of Increased Use of Personal Devices and Passive Data
    • Key Patient Engagement Technology Trends and Innovations
    • eCOA & ePRO: A Powerful Duo Serving Clinical Trials with Electronic Data Collection
    • Rise in Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions
    • Number of Registered Clinical Studies (in Thousands) Worldwide for the Period 2010-2023
    • Clinical Trials in the US: % Change in Trial Starts by Therapy Area for 2020 Vs 2019
    • Percentage Breakdown of Endpoint Adjudication Committees (EAC) Trials by Therapeutic Area: 2023E
    • COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials
    • Digital Health Venture Funding in the US (in $ Billion) for the Years 2015-2023
    • Trends in Clinical Trials Space to Influence Market Demand
    • Shift towards Decentralized/Virtual Clinical Trials to Boost Market Prospects
    • Global Virtual Clinical Trials Market Size (in US$ Billion) for the Years 2022, 2024, 2026 and 2028
    • Global Virtual Clinical Trials Market by Indication (in %) for 2023E
    • Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development
    • Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials
    • Growing Volumes of Data Generation in Decentralized Trials: A Challenge
    • Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market
    • Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region/Country for 2020 and 2027
    • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • COVID-19 and Implications for Drug Development Regulations & Processes
    • Rise in Telemedicine Services Present Market Opportunities
    • Global Telehealth Market (In US$ Million) for Years 2022, 2024, 2026 and 2028
    • Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects
    • Smartphone Adoption Rate as a Percentage of Connections by Region for 2022 and 2030
    • Mobile Device Use in Healthcare Settings: % Usage by Type of Mobile Device
    • Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems
    • Moving over Paper Pains & Mastering the Art of Real-Time Data Collection with ePRO
    • Delivering Better Data: A Key Benefit of ePRO
    • Factors Ensuring Success of ePRO Implementations
    • ePatient Reported Outcomes (PROs) Gain Importance in Oncology Studies
    • Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems
    • Integrating AI into ePRO Improves the Efficiency of ePRO Data Collection and Assessment
    • Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions
    • Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth
    • Global eCOA Market Breakdown by Delivery Mode (in %) for 2023E
    • eCOA Usage by Clinical Trial Phase (in %) for 2021
    • eCOA Grants The Best Route to Improve Data Quality & Patient Experience for Clinical Trials
    • Benefits Offered by eCOA Systems over the Paper-Based Systems in Trials
    • How to Successfully Implement eCOA Systems in Clinical Trials?
    • New Technologies & Approaches with Potential to Augment Statistical Prowess of eCOA
    • Technological Trends Transforming eCOA Solutions Market
    • Future Trends in eCOA Market: A Review
    • UAT, Challenges and Embedded UAT for eCOAs
    • Benefits of BYOD for eCOAs
    • E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market
    • Major Benefits of ePatient Diary
    • eCOA & ePRO to Help Mental Health Research Shed the Taboo Status & Move Forward
    • Intriguing Perks of eCOA & ePRO for Mental Health Research
    • Increase in Healthcare Spending to Propel Demand
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boost Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Aging World Population to Drive Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Challenges Facing Companies Implementing eCOA, ePRO & Patient-Centric Clinical Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World ePRO, E-Patient Diaries and eCOA Market Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for eClinical Outcome Assessments (eCOAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for eClinical Outcome Assessments (eCOAs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for ePatient Reported Outcomes (ePROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for ePatient Reported Outcomes (ePROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Clinician Reported Outcomes (ClinROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Clinician Reported Outcomes (ClinROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for ePatient Diaries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for ePatient Diaries by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Performance Outcomes (PerfOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Performance Outcomes (PerfOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Observer Reported Outcomes (ObsROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Observer Reported Outcomes (ObsROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Clinical Trial Sponsors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Canada 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • TABLE 34: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Japan 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Japan 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • TABLE 38: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: China 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 42: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 43: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • TABLE 48: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: France 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 50: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • TABLE 52: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Germany 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 54: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Germany 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 56: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Italy 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 58: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Italy 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • TABLE 60: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: UK 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 62: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: UK 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 64: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 72: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Rest of World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
    • TABLE 74: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION